Literature DB >> 21041908

Advances in nucleoside monophosphate prodrugs as anti-HCV agents.

Drew R Bobeck1, Raymond F Schinazi, Steven J Coats.   

Abstract

Nucleoside monophosphate prodrugs that are eventually bioconverted to the active nucleoside triphosphate (NTP) offer the potential to deliver increased intracellular NTP levels and/or organ-specific NTP enhancement. There are several classes of monophosphate prodrugs that have been applied to HCV drug discovery, and some of these approaches are currently being evaluated in humans. This review discusses recent advances in monophosphate prodrug approaches to improve oral absorption, stability and pharmacokinetic profile, including their advantages and potential pitfalls.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21041908      PMCID： PMC7733240          DOI： 10.3851/IMP1667

Source DB:  PubMed          Journal:  Antivir Ther        ISSN： 1359-6535


  51 in total

Review 1.  Side effects of therapy of hepatitis C and their management.

Authors:  Michael W Fried
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

Review 2.  Hepatitis C: the clinical spectrum of disease.

Authors:  J H Hoofnagle
Journal:  Hepatology       Date:  1997-09       Impact factor: 17.425

Review 3.  Hepatitis C: a review for primary care physicians.

Authors:  Tom Wong; Samuel S Lee
Journal:  CMAJ       Date:  2006-02-28       Impact factor: 8.262

4.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

Review 5.  Prodrug approaches of nucleotides and oligonucleotides.

Authors:  Päivi Poijärvi-Virta
Journal:  Curr Med Chem       Date:  2006       Impact factor: 4.530

Review 6.  Physiological concentrations of purines and pyrimidines.

Authors:  T W Traut
Journal:  Mol Cell Biochem       Date:  1994-11-09       Impact factor: 3.396

7.  Alkoxyalkyl esters of 9-(s)-(3-hydroxy-2-phosphonomethoxypropyl) adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV transgenic mice in vivo.

Authors:  John D Morrey; Brent E Korba; James R Beadle; David L Wyles; Karl Y Hostetler
Journal:  Antimicrob Agents Chemother       Date:  2009-04-27       Impact factor: 5.191

8.  Clinical outcomes after transfusion-associated hepatitis C.

Authors:  M J Tong; N S el-Farra; A R Reikes; R L Co
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

Review 9.  Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting.

Authors:  Fujun Li; Hans Maag; Tom Alfredson
Journal:  J Pharm Sci       Date:  2008-03       Impact factor: 3.534

Review 10.  Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.

Authors:  Uwe Koch; Frank Narjes
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295
View more
  13 in total

Review 1.  Prodrugs of phosphonates and phosphates: crossing the membrane barrier.

Authors:  Andrew J Wiemer; David F Wiemer
Journal:  Top Curr Chem       Date:  2015

2.  Efficient synthesis of nucleoside aryloxy phosphoramidate prodrugs utilizing benzyloxycarbonyl protection.

Authors:  Jong Hyun Cho; Franck Amblard; Steven J Coats; Raymond F Schinazi
Journal:  Tetrahedron       Date:  2011-07-29       Impact factor: 2.457

3.  Synthesis of purine modified 2'-C-methyl nucleosides as potential anti-HCV agents.

Authors:  Hong-wang Zhang; Longhu Zhou; Steven J Coats; Tamara R McBrayer; Phillip M Tharnish; Lavanya Bondada; Mervi Detorio; Sarah A Amichai; Melissa D Johns; Tony Whitaker; Raymond F Schinazi
Journal:  Bioorg Med Chem Lett       Date:  2011-09-20       Impact factor: 2.823

Review 4.  Synthesis of nucleoside phosphate and phosphonate prodrugs.

Authors:  Ugo Pradere; Ethel C Garnier-Amblard; Steven J Coats; Franck Amblard; Raymond F Schinazi
Journal:  Chem Rev       Date:  2014-08-21       Impact factor: 60.622

5.  Synthesis and Anti-HCV Activity of a Novel 2',3'-Dideoxy-2'-α-fluoro-2'-β-C-methyl Guanosine Phosphoramidate Prodrug.

Authors:  Wenquan Yu; Ertong Li; Zhigang Lv; Ke Liu; Xiaohe Guo; Yuan Liu; Junbiao Chang
Journal:  ACS Med Chem Lett       Date:  2017-05-01       Impact factor: 4.345

6.  Synthesis and evaluation of novel potent HCV NS5A inhibitors.

Authors:  Hongwang Zhang; Longhu Zhou; Franck Amblard; Junxing Shi; Drew R Bobeck; Sijia Tao; Tamara R McBrayer; Phillip M Tharnish; Tony Whitaker; Steven J Coats; Raymond F Schinazi
Journal:  Bioorg Med Chem Lett       Date:  2012-05-24       Impact factor: 2.823

7.  Efficient synthesis of exo-N-carbamoyl nucleosides: application to the synthesis of phosphoramidate prodrugs.

Authors:  Jong Hyun Cho; Steven J Coats; Raymond F Schinazi
Journal:  Org Lett       Date:  2012-05-03       Impact factor: 6.005

8.  Antiviral activity of nucleoside analogues against norovirus.

Authors:  Verónica P Costantini; Tony Whitaker; Leslie Barclay; David Lee; Tamara R McBrayer; Raymond F Schinazi; Jan Vinjé
Journal:  Antivir Ther       Date:  2012-08-14

9.  Inhibition of hepatitis C viral RNA-dependent RNA polymerase by α-P-boranophosphate nucleotides: exploring a potential strategy for mechanism-based HCV drug design.

Authors:  Marcus Adrian Cheek; Mariam L Sharaf; Mikhail I Dobrikov; Barbara Ramsay Shaw
Journal:  Antiviral Res       Date:  2013-03-04       Impact factor: 5.970

Review 10.  Chutes and ladders in hepatitis C nucleoside drug development.

Authors:  Steven J Coats; Ethel C Garnier-Amblard; Franck Amblard; Maryam Ehteshami; Sheida Amiralaei; Hongwang Zhang; Longhu Zhou; Sebastien R L Boucle; Xiao Lu; Lavanya Bondada; Jadd R Shelton; Hao Li; Peng Liu; Chengwei Li; Jong Hyun Cho; Satish N Chavre; Shaoman Zhou; Judy Mathew; Raymond F Schinazi
Journal:  Antiviral Res       Date:  2013-11-23       Impact factor: 5.970
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.